Significance of Endothelial Progenitor Cells in Subjects With Diabetes

Fadini, Gian Paolo; Sartore, Saverio; Agostini, Carlo; Avogaro, Angelo

doi:10.2337/dc06-2305

Cited by 173 publications

(149 citation statements)

References 87 publications

Supporting

Mentioning

134

Contrasting

Unclassified

Order By: Relevance

“…It is well established that EPCs are nowdays considered a mirror of cardiovascular health [21] and their circulating levels are decreased in diabetic subjects compared to healthy controls [10].Tissue ischemia is the strongest stimulus for EPCs mobilization from bone marrow [11]. Avogardo et al (2011) [8] proposed that the majority of cytokines which mediate EPCs mobilization do so via modulation SDFα or its receptor, CXCR4.…”

Section: Resultsmentioning

confidence: 99%

“…The retinal endothelium has a limited capacity of self-reparation since it is made of terminally differentiated cells with a low proliferative potential. That is why the reparation process is accomplished through the endothelial progenitor cells (EPCs) located in the bone marrow and mobilized into circulation mostly via the up regulation of the stromal derived factor α (SDFα) or its receptor [10]. The impairment in this process is demonstrated in experimental diabetes models [11].…”

Section: According To the Wisconsin Epidemiologic Study Of Diabetic Rmentioning

confidence: 99%

See 1 more Smart Citation

Circulating Dipeptidyl Peptidase-4 Activity is Associated with Diabetic Retinopathy in Type 1 Diabetic Patients

Blaslov

Bulum

Duvnjak

2015

European Journal of Ophthalmology

View full text Add to dashboard Cite

Purpose Diabetic retinopathy (DR) is the most frequent complication among patients with type 1 diabetes mellitus (T1DM). Dipeptidyl peptidase–4 (DPP4) is a protease with elevated activity in patients with T1DM. Several studies indicate that DPP4 inhibitors might have beneficial effect on nonproliferative retinopathy (NPR) development as well as on its progression to proliferative retinopathy (PR). We aimed to explore the relationship between serum DPP4 activity and DR in patients with T1DM. Methods This cross-sectional study recruited 44 patients with T1DM. The DPP4 activity was measured by colorimetric assay in a microplate reader. Photodocumented retinopathy status was made according to the EURODIAB protocol. Results A total of 28 (63.6%) patients were men, mean age 45.36 years, diabetes duration 23.71 years, glycated hemoglobin A1c (HbA1c) 7.4%. Patients were stratified into 2 groups according to retinopathy prevalence. Group 1 comprised 14 (31.85%) patients with DR absence while the second group consisted of 30 (68.15%) patients with both PR and NPR. Group 1 had lower fasting serum DPP4 activity (25.85 vs 33.84 U/L, p<0.001) when compared to the second group. In the binary logistic regression model adjusted for age, sex, diabetes duration, and HbA1c level, DPP4 activity was associated with DR prevalence (odds ratio 1.887 [1.073-3.321]). Conclusions Serum DPP4 activity may be independently associated with both DR types in patients with T1DM. Further study is warranted to elucidate whether there is an association between DPP4 activity and DR severity and/or progression.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: According To the Wisconsin Epidemiologic Study Of Diabetic Rmentioning

confidence: 99%

Circulating Dipeptidyl Peptidase-4 Activity is Associated with Diabetic Retinopathy in Type 1 Diabetic Patients

Blaslov

Bulum

Duvnjak

2015

European Journal of Ophthalmology

View full text Add to dashboard Cite

show abstract

“…Clinical studies on diabetic complications provided strong evidence of EPC alterations in the setting of macrovascular disease, while there are fewer data on microangiopathy, with the exception of retinopathy [3]. In conductance vessels, EPC impairment can be related to the development of atherosclerosis, while in resistance vessels it may lead to microvascular rarefaction.…”

mentioning

confidence: 99%

“…This would be followed by impaired restoration of blood flow in ischaemic tissues, as a result of defective angiogenesis, contributing to disease progression [2]. This is why the observation that type 1 and type 2 diabetic patients have dysfunctional and severely reduced EPCs has led to a novel pathogenic model of diabetic complications [3].…”

mentioning

confidence: 99%

An underlying principle for the study of circulating progenitor cells in diabetes and its complications

Fadini

2008

Diabetologia

View full text Add to dashboard Cite

“…Traditionally, neoangiogenesis after ischaemia and reendothelisation after endothelial injury were considered to be accomplished through the activation, proliferation and migration of resident endothelial cells. However, following the discovery of endothelial progenitor cells (EPCs), defective re-endothelisation and neoangiogenesis in diabetes have been attributed to circulating EPCs with an impaired regenerative capacity [4,8], thereby placing circulating cells at the centre of a new pathophysiological model of diabetic vascular disease [9,10]. Interest around these cells has been further amplified by the possibility of developing cell-based therapies for vascular complications [11,12].…”

mentioning

confidence: 99%

A reappraisal of the role of circulating (progenitor) cells in the pathobiology of diabetic complications

Fadini

2013

Diabetologia

View full text Add to dashboard Cite

Traditionally, the development of diabetic complications has been attributed to the biochemical pathways driving hyperglycaemic cell damage, while reparatory mechanisms have been long overlooked. A more comprehensive view of the balance between damage and repair suggests that an impaired regenerative capacity of bone marrow (BM)-derived cells strongly contributes to defective re-endothelisation and neoangiogenesis in diabetes. Although recent technological advances have redefined the biology and function of endothelial progenitor cells (EPCs), interest in BM-derived vasculotropic cells in the setting of diabetes and its complications remains high. Several circulating cell types of haematopoietic and non-haematopoietic origin are affected by diabetes and are potentially involved in the pathobiology of chronic complications. In addition to classical EPCs, these include circulating (pro-)angiogenic cells, polarised monocytes/macrophages (M1 and M2), myeloid calcifying cells and smooth muscle progenitor cells, having disparate roles in vascular biology. In parallel with the study of elusive progenitor cell phenotypes, it has been recognised that diabetes induces a profound remodelling of the BM stem cell niche. The alteration of circulating (progenitor) cells in the BM is now believed to be the link among distant end-organ complications. The field is rapidly evolving and interest is shifting from specific cell populations to the complex network of interactions that orchestrate trafficking of circulating vasculotropic cells.

show abstract

Significance of Endothelial Progenitor Cells in Subjects With Diabetes

Cited by 173 publications

References 87 publications

Circulating Dipeptidyl Peptidase-4 Activity is Associated with Diabetic Retinopathy in Type 1 Diabetic Patients

Circulating Dipeptidyl Peptidase-4 Activity is Associated with Diabetic Retinopathy in Type 1 Diabetic Patients

An underlying principle for the study of circulating progenitor cells in diabetes and its complications

A reappraisal of the role of circulating (progenitor) cells in the pathobiology of diabetic complications

Contact Info

Product

Resources

About